|
Market Closed -
Other stock markets
|
Pre-market 16:13:41 | |||
| 312.31 USD | -1.81% |
|
312.01 | -0.10% |
| 04-15 | Terremoto Biosciences, Inc. announced that it has received $108 million in funding from a group of investors | CI |
| 04-15 | Molecular Partners AG Announces Board and Committee Appointments | CI |
Company Valuation: BeOne Medicines AG
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 27,843 | 22,843 | 18,862 | 19,667 | 33,619 | 34,635 | - | - |
| Change | - | -17.96% | -17.43% | 4.27% | 70.94% | 3.02% | - | - |
| Enterprise Value (EV) 1 | 24,097 | 19,511 | 16,564 | 18,058 | 30,091 | 31,179 | 30,416 | 28,108 |
| Change | - | -19.03% | -15.1% | 9.02% | 66.64% | 3.62% | -2.45% | -7.59% |
| P/E ratio | -17.8x | -11.3x | -21.3x | -30.2x | 120x | 56.4x | 33.8x | 26.4x |
| PBR | 4.03x | 5.17x | 5.32x | 5.84x | 7.9x | 7.26x | 5.57x | 4.25x |
| PEG | - | -0.4x | 0.4x | 1.1x | -1x | 0x | 0.5x | 0.9x |
| Capitalization / Revenue | 23.7x | 16.1x | 7.67x | 5.16x | 6.29x | 5.42x | 4.71x | 4.25x |
| EV / Revenue | 20.5x | 13.8x | 6.74x | 4.74x | 5.63x | 4.88x | 4.14x | 3.45x |
| EV / EBITDA | -17.3x | -11.3x | -14.8x | -45.6x | 51.1x | 32.7x | 21.6x | 14.1x |
| EV / EBIT | -16.7x | -10.9x | -13.7x | -31.8x | 67.3x | 41.3x | 26x | 17.6x |
| EV / FCF | -15.4x | -10.7x | -9.63x | -28.5x | 32x | 52.6x | 30.1x | 19.7x |
| FCF Yield | -6.48% | -9.34% | -10.4% | -3.51% | 3.13% | 1.9% | 3.32% | 5.07% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -15.23 | -19.43 | -8.45 | -6.12 | 2.53 | 5.533 | 9.23 | 11.83 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 1,176 | 1,416 | 2,459 | 3,810 | 5,343 | 6,388 | 7,348 | 8,148 |
| EBITDA 1 | -1,392 | -1,723 | -1,120 | -396.4 | 588.8 | 954.8 | 1,409 | 1,991 |
| EBIT 1 | -1,439 | -1,790 | -1,208 | -568.2 | 447.1 | 754.1 | 1,172 | 1,600 |
| Net income 1 | -1,413 | -2,004 | -881.7 | -644.8 | 286.9 | 646 | 1,051 | 1,393 |
| Net Debt 1 | -3,746 | -3,332 | -2,297 | -1,609 | -3,528 | -3,456 | -4,219 | -6,527 |
| Reference price 2 | 270.93 | 219.94 | 180.36 | 184.71 | 303.81 | 312.31 | 312.31 | 312.31 |
| Nbr of stocks (in thousands) | 102,770 | 103,859 | 104,578 | 106,476 | 110,658 | 110,899 | - | - |
| Announcement Date | 25/02/22 | 27/02/23 | 26/02/24 | 27/02/25 | 26/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 56.45x | 4.88x | 32.65x | -.--% | 34.63B | |
| 31.13x | 5.45x | 16.88x | 1.06% | 45.74B | |
| -19.45x | 440.43x | -18.96x | -.--% | 31.32B | |
| 21.62x | 2.46x | 10.62x | -.--% | 29.49B | |
| 33.64x | 8.35x | 21.5x | 0.37% | 28.78B | |
| 30.08x | 4.88x | 22.21x | -.--% | 14.7B | |
| 23.37x | 2.03x | 8.92x | 1.09% | 14.34B | |
| -17.88x | 14.8x | -20.01x | -.--% | 12.35B | |
| Average | 19.87x | 60.41x | 9.23x | 0.31% | 26.42B | |
| Weighted average by Cap. | 23.34x | 70.06x | 11.58x | 0.35% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- ONC Stock
- Valuation BeOne Medicines AG
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition